Juggernaut Capital Partners Foundation Consumer Healthcare is funded by Juggernaut Capital Partners.
Is Foundation Consumer Healthcare publicly traded?
It’s who we are. – Foundation Consumer Healthcare is the #1 privately-held over-the-counter (OTC) healthcare manufacturer in the United States. We’re dedicated to improving consumers’ lives by developing and growing a portfolio of differentiated over-the-counter (OTC) products.
Who owns GSK consumer healthcare?
Update – GSK Consumer Healthcare | GSK Issued: London UK GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of £50 billion comprising £41.7 billion in cash and £8.3 billion in Unilever shares.
- The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%.
- GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects.
- The Board of GSK is strongly focused on maximising value for GSK shareholders and has carefully evaluated each Unilever proposal.
In doing so, the Board and its advisers assessed the proposals relative to the financial planning assessments completed to support the proposed demerger of the business in mid-2022, including the sales growth outlook set out below. Global leader in Consumer Healthcare The Consumer Healthcare business has been transformed since 2014 through the successful integrations of GSK’s business with the Novartis consumer health portfolio in 2015 and the Pfizer portfolio in 2019.
Importantly, this transformation has also provided a platform to scale and optimise many aspects of the Consumer Healthcare business including divesting lower growth brands, introducing a new R&D/innovation model, optimising the supply chain and manufacturing network, alongside continued investment in new digital, data and analytic platforms and capabilities.
This has resulted in the creation of a leading global consumer healthcare business with annual sales of £9.6 billion in 2021 1, The business has an exceptional portfolio of world-class, category-leading brands; global scale with footprint and distribution capability to serve more than 100 markets; strong brand building, innovation and digital capabilities; and offers a unique proposition that combines trusted science with human understanding.
- The business is led by a highly skilled management team with deep experience in consumer healthcare and FMCG with strong commitment to delivery on its purpose and growth ambitions.
- Superior growth and highly attractive financial profile The business is well-positioned to sustainably grow ahead of its categories in the years to come.
The fundamentals for the £150 billion consumer healthcare sector are strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle class, and sizeable unmet consumer needs. Over the period 2019-2021 the Consumer Healthcare business delivered a 4% organic sales growth CAGR 2 outpacing its categories and despite the adverse impact of the COVID pandemic.
Superior sales growth for the business is expected to result from a strategy that puts the consumer at the heart of the business to better address every-day health and wellness needs, in particular by increasing household penetration of its leading brands and capitalising on new and emerging growth opportunities arising from innovation and the use of new technologies and digital platforms, all underpinned by continued strong execution and financial discipline.
Over the medium term, superior sales growth is expected to be primarily driven by continued momentum of key brands in Oral Care, VMS, and Pain Relief; accelerating innovation in the US and China; and further growth in emerging markets.
Reflecting these trends, and the investments made and planned for the business, the Board of GSK is confident that the Consumer Healthcare business can sustainably deliver annual organic sales growth in the range of 4-6% (CER) over the medium term.The combination of superior organic sales growth, operating margin expansion and consistent high cash generation will, we believe, offer both existing and prospective shareholders a highly attractive financial profile that facilitates continued investment in growth, the delivery of attractive returns and the opportunity of continued participation in long-term value creation. Proposals fundamentally failed to reflect the intrinsic value of the business and its potential The Board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK therefore remains focused on executing its proposed demerger of the Consumer Healthcare business, to create a new independent global category-leading consumer company which, subject to approval from shareholders, is on track to be achieved in mid-2022. Capital Markets event GSK intends to share further details of the strategy, brands, capabilities and operations, including detailed financial information and future growth ambitions for the new Consumer Healthcare business at a virtual Capital Markets Day for investors and analysts on Monday 28th February 2022. Notes 1 Unaudited. (2021 full year results for GSK due to be announced on 9th February 2022) 2 Excluding the impact of brands divested/ under review, on a CER basis
About GSK GSK is a science-led global healthcare company. For further information please visit, Cautionary statement regarding forward looking statements This announcement contains statements that are, or may be deemed to be, “forward-looking statements”.
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company’s Annual Report on Form 20-F for 2020, GSK’s 2021 Q3 Results and any impacts of the COVID-19 pandemic.
GSK undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.
Did Unilever buy GSK consumer?
Unilever will not raise rejected 50 bln pound bid for GSK consumer arm Jan 19 (Reuters) – (This January 19 story corrects to make clear Pfizer has stake in consumer healthcare business, paragraph 6.) Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline’s consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.U.S.-listed shares of Unilever rose 10.1% on the news, while GSK’s fell 2.8%.
The two stocks also trade on the FTSE, where the day’s trading had closed. GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids “fundamentally undervalued” the business and its prospects.
It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit. Unilever said in a statement it had noted these but “determined that it does not change our view on fundamental value.
- Accordingly, we will not increase our offer above £50 bln”.
- A spokesperson for GSK responded that the group was strongly focused on maximising shareholder value and very confident in the future of the consumer healthcare business in which Pfizer has a 32% stake.
- The logo of Unilever in Rotterdam, Netherlands August 21, 2018.
REUTERS/Piroschka van de Wouw/File Photo “The Consumer Healthcare business has an exceptional portfolio and offers existing and prospective shareholders a highly attractive financial profile supporting investment and future returns,” they added. In a statement rebuffing Unilever’s overtures last weekend, GSK said the bid failed to capture the unit’s potential, releasing new forecasts that projected annual organic sales growth of 4%-6% for the business, which made sales of 9.6 billion pounds last year, over the medium term.
This estimate was above its prior forecast of seeking to beat the consumer health market’s growth of about 4%.The British drug maker said it intends to further share details of its strategy for the consumer brands unit at an investor day on 28 February.The event would follow its fourth-quarter results on 9 February where it might also throw some light on its thinking.Unilever’s decision not to raise its bid comes after analysts and investors widely panned its offer, sending shares in the maker of Dove soap down 8% on Monday, on worries about the financial implications for the company. A source familiar with Pfizer’s strategy told Reuters earlier this week that GSK and Pfizer would open negotiations with Unilever’s boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds. ($1 = 0.7337 pounds) Reporting by Siddharth Cavale, Aby Jose Koilparambil in Bengaluru and Ludwig Burger in Frankfurt; Editing by Devika Syamnath, Alexandra Hudson Our Standards:
: Unilever will not raise rejected 50 bln pound bid for GSK consumer arm
What company owns Plan B stock?
The men profiting from demand for Plan B – Since the Supreme Court overturned Roe v. Wade, many women have been rushing to stock up on emergency contraception pills, in hopes of exerting more control over their bodies, or because they’re worried that the products could be restricted.
Birth control remains legal across the United States.) Drugstores have found themselves in short supply of the pills, and some are limiting purchases, The uptick in demand could add up to huge profits for the two private equity firms behind the most well-known morning-after pill, Plan B. It might also put Plan B in the middle of the abortion rights fight.
The all-male teams of investors behind Plan B are poised to make big bucks, According to the websites of the two private equity firms, Kelso and Juggernaut, only men make up the teams overseeing the maker of the top-selling emergency contraception in the United States.
- And their paydays could be big.
- One dose of brand-name Plan B typically sells for around $46.
- And it’s probably quite profitable: It had a more than 85 percent profit margin when it was sold as a prescription drug by Barr, said David Woodburn, a former analyst who covered the company.
- Neither firm responded to DealBook’s requests for comment about the gender makeup of their teams.) Plan B’s maker had exclusive marketing rights for three years after the F.D.A.
extended the medication’s over-the-counter use to all ages in 2013. That exclusivity plays a big role in how well-known the brand is. The brand has competition from cheaper generic versions, but women often prefer familiar brands of health products like emergency contraception, analysts say.
Teva, which acquired Barr, sold Plan B to Kelso and Juggernaut in 2017 for $675 million. The firms run Plan B through Foundation Consumer Healthcare, a company that owns several over-the-counter brands, including the cold medicine Dimetapp. The language on the emergency pill’s packaging could pave the way for its restriction,
Plan B works mainly by stopping the release of an egg from the ovaries. But some believe that its maker had to use certain wording to get it approved by the F.D.A. in 2006 for over-the-counter use. As such, Plan B’s label says it may also prevent a fertilized embryo from attaching to the uterus.
Who is the biggest manufacturer of Plan B?
Teva to receive $675 million cash proceeds to progress repayment of term loan debt Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the sale of Plan B One-Step ® and Teva’s value brands of emergency contraception to Foundation Consumer Healthcare in a $675 million cash transaction.
“Today’s announcement, coupled with the recent completion of the sale of PARAGARD ®, exhibits Teva’s commitment to divest non-core businesses to ensure that we are even more focused and efficient in this rapidly changing and highly-competitive environment,” stated Michael McClellan, interim CFO of Teva.
“Teva is extremely pleased to complete the sale of Plan B One-Step ® and value brands of emergency contraception, which brings a significant influx of cash into the organization to further progress our ability to repay term loan debt while also providing a clear path forward for these important emergency contraception products to continue to be available.” Teva continues to progress and actively pursue additional divestiture opportunities, including the previously announced agreement with CVC Capital Partners for the sale of the remaining assets of its global Women’s Health business.
Teva expects to generate at least $2.3 billion in total proceeds from the sale of these businesses, as well as additional asset sales to be executed by year end 2017. Morgan Stanley acted as financial advisor to Teva, Ernst & Young served as accounting advisor and Goodwin Procter is Teva’s legal counsel for this transaction.
Foundation Consumer Healthcare is owned by affiliates of Juggernaut Capital Partners and Kelso & Company. Jefferies LLC, Sawaya Segalas & Co., LLC and Barclays acted as financial advisors to Foundation Consumer Healthcare and Robinson Bradshaw are Foundation Consumer Healthcare’s legal counsel for the transaction.
Skadden, Arps, Slate, Meagher & Flom LLP acted as legal adviser to Kelso & Company. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in over 60 markets every day.
Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products.
Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva’s net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com, Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the completion of the Plan B One-Step® divestiture which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such differences include risks relating to:
the potential that the expected benefits and opportunities related to the disposition may not be realized or may take longer to realize than expected; litigation in respect of either company or the disposition; our ability to complete additional dispositions, including our ability to identify purchasers and negotiate terms acceptable to us; our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a downgrade of our credit ratings; our business and operations in general, including: uncertainties relating to our recent senior management changes; our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel, including those who joined us as part of the Actavis Generics acquisition; the restructuring of our manufacturing network, including potential related labor unrest; the impact of continuing consolidation of our distributors and customers; variations in patent laws that may adversely affect our ability to manufacture our products; our ability to consummate dispositions on terms acceptable to us; adverse effects of political or economic instability, major hostilities or terrorism on our significant worldwide operations; and our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; governmental investigations into sales and marketing practices; potential liability for sales of generic products prior to a final resolution of outstanding patent litigation; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors.” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com, Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Pharmaceutical Industries Ltd. IR Contacts: United States Kevin C. Mannix, 215-591-8912 Ran Meir, 215-591-3033 or Israel Tomer Amitai, 972 (3) 926-7656 or PR Contacts: Israel Iris Beck Codner, 972 (3) 926-7208 or United States Denise Bradley, 215-591-8974 Michelle Larkin, 610-786-7335
Who are the shareholders of EC Healthcare?
BEAUTY FARM MEDICAL AND HEALTH INDUSTRY INC. QB NET HOLDINGS CO.,LTD.2022.
|Lyn Wade Lu||Co-Chief Executive Officer & Executive Director|
|Chi Fai Tang||Chairman & Co-Chief Executive Officer|
|Heung Wing Lee||Finance Director|
Is GSK owned by Pfizer?
The European Commission has approved, under the EU Merger Regulation, the acquisition of Pfizer’s Consumer Health Business by GlaxoSmithKline.
Did Pfizer sell consumer health?
Dive Brief: –
Pfizer plans to sell its shares in a consumer health joint venture with GlaxoSmithKline after the business is spun off into a new standalone corporation called Haleon. GSK will put at least 80% of its 68% holding in the joint venture into Haleon, which is set to begin trading on the London Stock Exchange on July 18. Pfizer currently owns the other 32% and will exit the business “in a disciplined manner,” subject to several conditions, Pfizer said Wednesday, Both companies will refrain from selling shares in the new venture for some time. Under the agreement, a lock-up will continue through Nov.10 unless Haleon releases certain financial results earlier.
Who is the biggest shareholder of GlaxoSmithKline?
Threadneedle Asset Management Ltd.
What happened to GSK consumer healthcare?
GSK plc (LSE/NYSE: GSK) has today (Monday 18 July 2022) completed the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. The shares of Haleon plc (ticker “LSE: HLN”) will be admitted at 8.00 a.m. today to the Premium Listing segment of the Official List and to trading on the Main Market of the London Stock Exchange (“LSE”).
- It is expected that American Depositary Shares representing shares of Haleon plc (ticker: “NYSE: HLN”) (“Haleon ADSs”) will commence “regular-way” trading on the New York Stock Exchange (the “NYSE”) at market open on Friday 22 July 2022.
- In addition, we expect that Haleon ADSs will begin trading on a “when-issued” basis on the NYSE from market open today up to and including Thursday 21 July 2022.
Each Haleon ADS represents two Haleon ordinary shares.
Will GSK consumer be sold?
Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon | GSK Issued: London UK On 23 June 2021 at its Investor Update, GSK plc (“GSK” or the “Company”) confirmed its intention to separate its Consumer Healthcare business from the GSK Group to form Haleon plc (“Haleon”), an independent listed company.
It is proposed that the separation will be effected by way of a demerger (the “Demerger”) of at least 80 per cent. of GSK’s 68 per cent. holding in the Consumer Healthcare business to GSK shareholders. The Consumer Healthcare business is currently a joint venture between GSK and Pfizer Inc (“Pfizer”), with GSK holding a majority controlling interest of 68 per cent.
and Pfizer holding 32 per cent. GSK today confirms that the Circular in relation to the proposed Demerger, the consolidation of GSK shares (the “GSK Share Consolidation”) and certain new arrangements with Haleon and Pfizer to give effect to the Demerger (the “Related Party Transactions”), as well as the Prospectus in relation to the proposed admission of the Haleon ordinary shares, have each been submitted to the Financial Conduct Authority (“FCA”) for approval.
- It is expected that the Haleon ordinary shares will be admitted to the Premium listing segment of the Official List of the FCA and admitted to trading on the Main Market of the London Stock Exchange on Monday 18 July 2022.
- Application will also shortly be made to list American Depositary Shares (“ADSs”) representing Haleon ordinary shares on the New York Stock Exchange (“NYSE”).
The proposed Demerger is the most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people. Following the Demerger, GSK will focus purely on biopharmaceuticals, prioritising investment towards the development of innovative vaccines and specialty medicines.
Its R&D approach will continue to focus on the science of the immune system, use of human genetics and advanced technologies. Over the next five-year period, GSK expects to deliver compound annual growth in sales and adjusted operating profit of more than 5 per cent. and more than 10 per cent., respectively, at constant exchange rates (with 2021 as the base year).
Haleon is a new, world-leader in consumer healthcare with a clear strategy to outperform and run a responsible business. For prospective investors, it will offer an exceptional and focused portfolio of category-leading brands with an attractive footprint and competitive capabilities; a highly attractive financial profile of above market, medium-term annual organic revenue growth of 4 to 6 per cent.
combined with sustainable moderate, adjusted margin expansion on a constant currency basis, with strong cash generation and conversion. The Demerger is conditional on, among other things, the approval by GSK shareholders of the Demerger, the GSK Share Consolidation and the Related Party Transactions at a General Meeting, the receipt of all necessary mandatory governmental/regulatory approvals and the final approval of the Demerger by the GSK Board.
The General Meeting will be held at the Sofitel London Heathrow, Terminal 5, London Heathrow Airport, TW6 2GD on Wednesday 6 July 2022 at 2.30 p.m. (UK time). Further details will be set out in the Circular. Following completion of the Demerger and listing of Haleon, GSK intends to carry out the GSK Share Consolidation.
This is intended to provide consistency in the GSK share price pre- and post-separation (subject to interim market movements), in order to enable comparability between the Company’s earnings per share and share price with previous periods. GSK intends to announce its second quarter 2022 results on 27 July 2022 in which the Consumer Healthcare business will be treated as a discontinued operation.
Alongside this, Haleon will provide a trading update ahead of publishing its full interim results during September 2022. As part of the Demerger, GSK proposes to enter into new arrangements with Pfizer and Haleon and to amend certain existing arrangements with Pfizer.
Pfizer is a related party of GSK for the purposes of the Listing Rules by virtue of its 32 per cent. interest in the Consumer Healthcare business, which means that these new arrangements constitute related party transactions and require GSK shareholder approval at the General Meeting. GSK shareholder approval is also required in relation to the Demerger, which, due to its size, qualifies as a “Class 1” transaction for the purposes of the Listing Rules, and the GSK Share Consolidation.
Further details on Haleon, the Demerger and the Related Party Transactions are set out later in this release and in the Circular. A further announcement will be made once the Circular and the Prospectus have been approved for publication by the FCA.
When did GSK spin off consumer healthcare?
Demerger – completion and shareholder entitlement The Demerger completed on Monday 18 July 2022 and GSK shareholders received one Haleon plc share for each GSK plc share held at 6.00pm UK on Friday 15 July 2022. If you were a GSK shareholder at that time you are now a shareholder in both GSK and Haleon.
What are the foundation consumer brands?
Foundation Consumer Brands is a platform of over-the- counter health and wellness brands. – FCB’s portfolio includes Breathe Right® Nasal Strips, Children’s Dimetapp®, Anbesol®, Alavert®, Dristan®, Primatene Tablets® and FiberCon®. These products are sold in stores and online across the United States and internationally.
Why is Plan B so expensive?
Why does Plan B cost so much? – Plan B is generally more expensive than other morning-after pill options, because it’s the brand-name version. Some stores and telehealth platforms offer generic Plan B, which may be less expensive.
What is the stock symbol for Foundation Consumer Healthcare?
( FDNHQ ) trades on the OTCMKTS under the ticker symbol ‘FDNHQ.’
Why did Plan B fail?
What can cause Plan B to fail? – Plan B can fail to prevent pregnancy for the following reasons:
- Ovulation occurring before taking the medication
- Being overweight or obese
- Interaction with certain medications
Does Plan B have a 100% success rate?
The bottom line. Plan B is up to 89% effective at preventing pregnancy if taken within 72 hours (3 days) of unprotected sex. It’s very safe, well-tolerated, and won’t affect future fertility. Plan B isn’t effective during or after ovulation.
What company develops Plan B?
By: Published: 2008-09-04 Plan B: Emergency Contraceptive Pill Plan B is a progestin -only emergency contraceptive pill (ECP) that can be taken within seventy-two hours of unprotected sex in order to prevent an unwanted pregnancy, Plan B was created in response to the United States Food and Drug Administration’s (US FDA) 1997 request for new drug applications (NDAs) for a dedicated ECP product, and was approved for sales in the US in 1999.
- Duramed, a subsidiary of Barr Pharmaceuticals, manufactures Plan B for The Women’s Capital Corporation (WCC), which owns the patent for Plan B.
- This technology is important in part because it expands women’s reproductive rights by giving them greater control over their fertility.
- The mechanism of action of Plan B also raises questions about the moral status of the zygote,
Plan B consists of two 0.75 mg tablets of levonorgestrel, a type of synthetic progesterone or progestin, Current evidence suggests that the hormone works similarly to normal birth control by preventing ovulation, but previous studies have shown that it prevents implantation of a fertilized egg,
- ECPs had been prescribed off-label during the 1960s as high doses of hormonal birth control pills or as high doses of diethylstilbestrol (DES), a type of synthetic estrogen, for women who had been raped.
- Due to the many harmful side effects of DES, in the 1970s Dr.
- Albert Yuzpe did the first formal studies of combined estrogen-progestin ECPs with the goal of reducing the number of unintended pregnancies.
At this time, studies on progestin -only ECPs (like Plan B) were also being conducted in Latin America. The first dedicated ECP product was Postinor (containing only levonorgestrel ), distributed by Gedeon-Richter, a Hungarian firm, in Eastern Europe during the 1980s.
Plan B was developed in response to the US FDA’s request for NDAs for a dedicated ECP product. ECPs were first used for rape victims, but today they are more widely used by women for any type of situation where unprotected sex occurred and there is the risk of an unintended pregnancy, The creation of this technology was facilitated by the existence of hormonal birth control pills and synthetic hormones,
The development of the technology was motivated by population control and family planning concerns, as well as the desire to ensure reproductive rights, The FDA’s 1997 request for NDAs was in response to the Center for Reproductive Law and Policy’s 1994 request to the FDA that the packaging of certain oral contraceptives contain directions on how many pills to take for use as emergency contraception,
They denied this request, but instead put out the 1997 request for NDAs for a dedicated EC product, citing Dr. Yuzpe’s studies and the history of off-label use as proof of the safety and efficacy of such a technology. On 24 August 2006, Plan B was approved for over-the-counter (OTC) sales to individuals eighteen years and older.
This was after a 2003 application for OTC status for Plan B submitted by the WCC was rejected and the application was resubmitted in 2004 with the provision that it be sold OTC to individuals sixteen years and older. This technology is important to the embryo project because it is a method that expands women’s ability to control their fertility.
Its mechanism, specifically the evidence that it works by preventing implantation of a fertilized egg, has provoked a spectrum of reactions. Much of the opposition to Plan B stems from the belief that life begins at fertilization and that the zygote has moral status. One manifestation of this controversy is the creation of conscience clauses or claims that allow a pharmacist to refuse to dispense Plan B (as well as other drugs) on moral grounds.
Access to the drug has been framed as a moral and political concern. For example, when Wal-Mart first refused to sell Plan B, they explained that there was low demand for the drug, but others questioned the personal politics of individuals within the corporation.
Who manufactors Plan B?
From the makers of Plan B®, Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. What is Plan B® One-Step? Plan B® One-Step is emergency contraception that helps prevent pregnancy after birth control failure or unprotected sex.
Where is Plan B bought?
Where can I get the Plan B morning-after pill? – You can buy levonorgestrel morning-after pills (like Plan B One-Step, Take Action, My Way, Option 2, Preventeza, AfterPill, My Choice, Aftera, and EContra) over the counter without a prescription at drugstores and pharmacies.
Who invented Plan B?
Margaret Sanger (1879-1966) – Margaret Sanger devoted her life to legalizing birth control and making it universally available for women. Born in 1879, Sanger came of age during the heyday of the Comstock Act, a federal statute that criminalized contraceptives. Margaret Sanger believed that the only way to change the law was to break it. Starting in the 1910s, Sanger actively challenged federal and state Comstock laws to bring birth control information and contraceptive devices to women.
- Her fervent ambition was to find the perfect contraceptive to relieve women from the horrible strain of repeated, unwanted pregnancies.
- Tragedy Leads to Commitment Sanger’s commitment to birth control sprung from personal tragedy.
- One of eleven children born to a working class Irish Catholic family in Corning, New York, at age nineteen Margaret watched her mother die of tuberculosis.
Just 50 years old, her mother had wasted away from the strain of eleven childbirths and seven miscarriages. Facing her father over her mother’s coffin, Margaret lashed out, “You caused this. Mother is dead from having too many children.” Nurses Botched Abortions Determined to escape her mother’s fate, Sanger fled Corning to attend nursing school in the Catskills.
Eventually, she found work in New York City as a visiting nurse on the Lower East Side. It was there that Sanger saw her personal tragedy writ large in the lives of poor, immigrant women. Lacking effective contraceptives, many women, when faced with another unwanted pregnancy, resorted to five-dollar back-alley abortions.
It was after these botched abortions that Sanger was usually called in to care for the women. After experiencing many women’s trauma and suffering, Sanger began to shift her attention from nursing to the need for better contraceptives. Anger Turns to Action Sanger began to devote more and more of her time to her mission. Corbis Still More to Do But by the 1950s, although she had won many legal victories, Sanger was far from content. After 40 years of fighting to help women control their fertility, Sanger was extremely frustrated with the limited birth control options available to women.
Since the 1842 invention of the diaphragm in Europe and the introduction of the first full-length rubber condom in the U.S. in 1869, there had been no new advances in contraceptive methods. Sanger had championed the diaphragm, but after promoting it for decades, she knew it was still the least popular birth control method in America.
The diaphragm was highly effective, but it was expensive, awkward – and most women were too embarrassed to use it. Worried about Population Growth But Sanger, now in her seventies and in poor health, was not ready to give up. She had been dreaming of a “magic pill” for contraception since 1912.
- She was no longer just concerned about women suffering from unwanted pregnancies.
- Now, a firm believer in the theory of population control, she was also worried about the potential toll of unchecked population growth on the world’s limited natural resources.
- A “Magic Pill” Tired of waiting for science or industry to turn its attention to the problem, Margaret Sanger set out on a mission.
She sought someone to realize her vision of a contraceptive pill as easy to take as an aspirin. She wanted a pill that could provide women with cheap, safe, effective and female-controlled contraception. Her search ended in 1951 when she met Gregory Pincus, a medical expert in human reproduction who was willing to take on the project.
- Soon after, she found a sponsor for the research: International Harvester heiress Katharine McCormick.
- Their collaboration would lead to the FDA approval of Enovid, the first oral contraceptive, in 1960.
- With the advent of the Pill, Sanger accomplished her life-long goal of bringing safe and effective contraception to the masses.
A Dream Achieved Not only did Sanger live to see the realization of her “magic pill,” but four years later, at the age of 81, Sanger witnessed the undoing of the Comstock laws. In the 1965 Supreme Court case Griswold v. Connecticut, the court ruled that the private use of contraceptives was a constitutional right.